- Home
- AGMH vs GLMD Comparison
AGMH vs GLMD Comparison
Compare AGMH & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- GLMD
- Stock Information
- Founded
- AGMH 2015
- GLMD 2000
- Country
- AGMH Hong Kong
- GLMD Israel
- Employees
- AGMH N/A
- GLMD N/A
- Industry
- AGMH EDP Services
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- GLMD Health Care
- Exchange
- AGMH Nasdaq
- GLMD Nasdaq
- Market Cap
- AGMH 3.5M
- GLMD 4.1M
- IPO Year
- AGMH 2018
- GLMD 2014
- Fundamental
- Price
- AGMH $1.97
- GLMD $1.55
- Analyst Decision
- AGMH
- GLMD Hold
- Analyst Count
- AGMH 0
- GLMD 1
- Target Price
- AGMH N/A
- GLMD N/A
- AVG Volume (30 Days)
- AGMH 271.4K
- GLMD 396.4K
- Earning Date
- AGMH 08-12-2025
- GLMD 08-27-2025
- Dividend Yield
- AGMH N/A
- GLMD N/A
- EPS Growth
- AGMH N/A
- GLMD N/A
- EPS
- AGMH 6.43
- GLMD N/A
- Revenue
- AGMH $32,044,575.00
- GLMD N/A
- Revenue This Year
- AGMH N/A
- GLMD N/A
- Revenue Next Year
- AGMH N/A
- GLMD N/A
- P/E Ratio
- AGMH $0.28
- GLMD N/A
- Revenue Growth
- AGMH N/A
- GLMD N/A
- 52 Week Low
- AGMH $1.09
- GLMD $1.15
- 52 Week High
- AGMH $109.50
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- AGMH 31.23
- GLMD 38.58
- Support Level
- AGMH $2.30
- GLMD $1.79
- Resistance Level
- AGMH $2.59
- GLMD $2.09
- Average True Range (ATR)
- AGMH 0.24
- GLMD 0.20
- MACD
- AGMH -0.06
- GLMD -0.06
- Stochastic Oscillator
- AGMH 4.49
- GLMD 7.06
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.